OncoReview https://www.journalsmededu.pl/index.php/OncoReview <p>The main area of <em>OncoReview’s </em>&nbsp;scientific mission is the emerging field of interdisciplinary oncology, with particular emphasis on cardio-oncology. Scientific papers published in the journal concern modern diagnostic and therapeutic methods used in this population of patients, as well as all adverse events related to anticancer treatment. Objective assessment of the benefits and risks of new oncological drugs is a unique benefit of the published works.&nbsp;<br><span lang="en-GB"><br></span><span lang="en-GB"><strong>e-ISSN: </strong>2450-6125&nbsp; <strong>&nbsp; &nbsp; &nbsp; DOI: </strong>10.24292/01.OR<br><br><strong>Indexed in:&nbsp;</strong></span><strong>SCOPUS</strong>: SJR 2019 = 0.125; SNIP 2019= 0.099<br><span lang="en-GB">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Polish Journals Master List:&nbsp;<strong>20 points</strong>&nbsp;<br>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Index Copernicus: 116.25&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; <br>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Google Scholar<br>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Polish Medical Bibliography</span></p> <p>&nbsp;</p> Medical Education sp. z o.o. en-US OncoReview 2450-6125 <p><strong>Copyright: © Medical Education sp. z o.o.</strong>&nbsp;This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (<a href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</a>), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.</p> <p><em>Address reprint requests to: Medical Education, Marcin Kuźma (<a href="mailto:marcin.kuzma@mededu.pl">marcin.kuzma@mededu.pl</a>)</em></p> Are heated tobacco products a healthy alternative to cigarettes? https://www.journalsmededu.pl/index.php/OncoReview/article/view/1303 <p>As well as being an extremely widespread addiction, tobacco smoking is a well-known cause of numerous deaths around the world. Most (80–90%) of lung cancer cases occur among smokers. The awareness of harmful effects of smoking is growing constantly. Manufacturers of tobacco products have recently opted to face this challenge by marketing heated tobacco products. Based on the performed research, tobacco companies maintain that these products are less harmful. They advertise their products as a smokeless, unconventional, less harmful cigarette. Due to the short follow-up period, the studies on consequences of using heated tobacco products are still scarce. This article presents a review of the literature focused on the use of heated tobacco products as an alternative to traditional cigarettes.</p> Anna Romaszko-Wojtowicz Anna Doboszyńska Copyright (c) 2020 https://creativecommons.org/licenses/by-nc/4.0/ 2021-03-31 2021-03-31 11 1(41) 5 11 10.24292/01.OR.121310321 Cardiotoxicity of antiangiogenic drugs: causes and mechanisms https://www.journalsmededu.pl/index.php/OncoReview/article/view/1228 <p>Therapy with angiogenesis inhibitors is undoubtedly an advancement in cancer treatment; however, it is associated with a risk of developing cardiotoxicity, which most often manifests in myocardial contractile dysfunction or an increased risk of thromboembolic events. Heart failure is observed in 2–4% of patients treated with bevacizumab and in 3–8% of patients on antiangiogenic tyrosine kinase inhibitors.</p> <p>The proposed pathomechanisms underlying the impairment in systolic function during antiangiogenic drug treatment include mitochondrial dysfunction, a secondary reduction in cardiomyocyte ATP production and redox imbalance, which may contribute to pathological states known as “free radical diseases”. Additionally, therapy with angiogenesis inhibitors may also cause cardiac oxidative stress.</p> <p>The risk factors for cardiac complications include arterial hypertension, which is a known “class effect” of this class of drugs, as well as a number of other factors such as age, comorbidities, prior radiotherapy and baseline left ventricular ejection fraction.</p> <p>The cardiovascular diseases are still the first cause of death in the world. The more effective oncological treatment becomes, the more often comorbidities occur. This fact seems to demand interdisciplinary approach from investigators and practitioners.</p> <p>This article presents the current state of knowledge on the molecular mechanisms of cardiotoxicity of antiangiogenic drugs used in routine clinical practice.</p> Beata Tomaszewska Małgorzata Muzolf Radosław Grabysa Lubomir Bodnar Copyright (c) 2020 http://creativecommons.org/licenses/by-nc/4.0/ 2021-03-30 2021-03-30 11 1(41) 12 18 10.24292/01.OR.122030321 Myeloablative chemotherapy in testicular cancer patient https://www.journalsmededu.pl/index.php/OncoReview/article/view/1195 <p>Chemotherapy is the standard treatment for metastatic testicular cancers. The autologous hematopoietic stem cell transplantation is a salvage option for relapsed patients. The paper presents a case of a 20-year-old patient with stage IIIC non-seminoma treated with BEP chemotherapy and autologous transplantation of stem cells, which allowed to achieve durable remission.</p> Karolina Furgała Zuzanna Smuniewska Dawid Sigorski Maciej Michalak Lubomir Bodnar Copyright (c) 2021 Medical Education http://creativecommons.org/licenses/by-nc-nd/4.0/ 2021-03-24 2021-03-24 11 1(41) 19 21 10.24292/01.OR.121030321 Spontaneous tumor lysis syndrome in diffuse large B-cell lymphoma patient as a cause of acute kidney injury https://www.journalsmededu.pl/index.php/OncoReview/article/view/1327 <p>Idiopathic tumor lysis syndrome is a rare complication in the course of neoplastic disease. This condition requires an interdisciplinary therapeutic procedure. The presented case of spontaneous tumor lysis syndrome in the course of malignant large B-cell lymphoma describes an effective therapeutic approach in this type of cases.</p> Przemysław Kwiatkowski Grzegorz Kade Janusz Hałka Copyright (c) https://creativecommons.org/licenses/by-nc-nd/4.0/ 2021-04-15 2021-04-15 11 1(41) 22 26 10.24292/01.OR.121140421